Multilevel Resilience and Appointment Attendance Among African American/Black Adults with HIV: A Prospective Multisite Cohort Study

被引:0
作者
Wilson-Barthes, Marta G. [1 ]
Park, Jee Won [1 ,2 ]
Mugavero, Michael J. [3 ]
Napravnik, Sonia [4 ]
Carey, Michael P. [5 ]
Fava, Joseph L. [5 ]
Dale, Sannisha K. [6 ]
Earnshaw, Valerie A. [7 ]
Agil, Deana [4 ]
Howe, Chanelle J. [1 ]
Dulin, Akilah J. [8 ]
机构
[1] Brown Univ, Sch Publ Hlth, Dept Epidemiol, Ctr Epidemiol Res, 121 South Main St,Box G-S121-2, Providence, RI 02912 USA
[2] Univ Delaware, Program Epidemiol, Newark, DE USA
[3] Univ Alabama Birmingham, Dept Med, Div Infect Dis, Ctr AIDS Res, Birmingham, AL USA
[4] Univ North Carolina Chapel Hill, Gillings Sch Global Publ Hlth, Dept Med, Div Infect Dis,Sch Med,Dept Epidemiol, Chapel Hill, NC USA
[5] Brown Univ, Warren Alpert Med Sch, Miriam Hosp, Ctr Behav & Prevent Med,Dept Psychiat & Human Beha, Providence, RI USA
[6] Univ Miami, Dept Psychol, Coral Gables, FL USA
[7] Univ Delaware, Dept Human Dev & Family Sci, Newark, DE USA
[8] Brown Univ, Sch Publ Hlth, Ctr Hlth Promot & Hlth Equ, Dept Behav & Social Sci, Providence, RI USA
基金
美国国家卫生研究院;
关键词
Black; Clinic attendance; Clinical cohort; HIV; Neighborhood environment; Racial disparities; Resilience; Visit adherence; PARTIAL IDENTIFICATION; ADJUVANT CHEMOTHERAPY; STAGE-III; TRASTUZUMAB; IPILIMUMAB;
D O I
10.1097/EDE.0000000000001801
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background:Attending clinic appointments supports HIV viral suppression, yet racial disparities are documented. We assessed whether multilevel resilience resources were associated with appointment attendance among African American/Black (AA/B) adults living with HIV in the United States.Methods:We ascertained data from 291 AA/B clinical cohort participants from 2018 to 2021. We assessed resilience using the Multilevel Resilience Resource Measure. Binary outcomes were a nonrepeated indicator of attending >= 87.5% of scheduled HIV appointments over 12 months (i.e., visit adherence) and a repeated measure of attending appointments during two sequential 6-month follow-up windows (i.e., clinic attendance). Modified Poisson models estimated adjusted risk ratios (aRRs).Results:The aRR for clinic attendance among participants with greater versus lesser multilevel resilience resource endorsement was 0.95 (95% confidence interval: 0.88, 1.0). The aRR for visit adherence among participants with greater versus lesser multilevel resilience resource endorsement was 1.2 (0.95, 1.4).Conclusions:This analysis is one of the first to assess appointment attendance as a function of resilience. Findings should be confirmed in larger cohorts.
引用
收藏
页码:99 / 106
页数:8
相关论文
共 29 条
  • [1] [Anonymous], 2007, Identification for prediction and decision
  • [2] [Anonymous], 2023, NCI Dictionary of Cancer Terms: Survivor
  • [3] Value of information on preference heterogeneity and individualized care
    Basu, Anirban
    Meltzer, David
    [J]. MEDICAL DECISION MAKING, 2007, 27 (02) : 112 - 127
  • [4] EQ-5D and the EuroQol Group: Past, Present and Future
    Devlin, Nancy J.
    Brooks, Richard
    [J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2017, 15 (02) : 127 - 137
  • [5] Partial Identification of the Effects of Sustained Treatment Strategies
    Diemer, Elizabeth W.
    Shi, Joy
    Swanson, Sonja A.
    [J]. EPIDEMIOLOGY, 2024, 35 (03) : 308 - 312
  • [6] 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
    Earl, Helena M.
    Hiller, Louise
    Vallier, Anne-Laure
    Loi, Shrushma
    McAdam, Karen
    Hughes-Davies, Luke
    Harnett, Adrian N.
    Ah-See, Mei-Lin
    Simcock, Richard
    Rea, Daniel
    Raj, Sanjay
    Woodings, Pamela
    Harries, Mark
    Howe, Donna
    Raynes, Kerry
    Higgins, Helen B.
    Wilcox, Maggie
    Plummer, Chris
    Mansi, Janine
    Gounaris, Ioannis
    Mahler-Araujo, Betania
    Provenzano, Elena
    Chhabra, Anita
    Abraham, Jean E.
    Caldas, Carlos
    Hall, Peter S.
    McCabe, Christopher
    Hulme, Claire
    Miles, David
    Wardley, Andrew M.
    Cameron, David A.
    Dunn, Janet A.
    [J]. LANCET, 2019, 393 (10191) : 2599 - 2612
  • [7] Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
    Eggermont, Alexander M. M.
    Blank, Christian U.
    Mandala, Mario
    Long, Georgina, V
    Atkinson, Victoria
    Dalle, Stephane
    Haydon, Andrew
    Lichinitser, Mikhail
    Khattak, Adnan
    Carlino, Matteo S.
    Sandhu, Shahneen
    Larkin, James
    Puig, Susana
    Ascierto, Paolo A.
    Rutkowski, Piotr
    Schadendorf, Dirk
    Koornstra, Rutger
    Hernandez-Aya, Leonel
    Maio, Michele
    van den Eertwegh, Alfonsus J. M.
    Grob, Jean-Jacques
    Gutzmer, Ralf
    Jamal, Rahima
    Lorigan, Paul
    Ibrahim, Nageatte
    Marreaud, Sandrine
    van Akkooi, Alexander C. J.
    Suciu, Stefan
    Robert, Caroline
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (19) : 1789 - 1801
  • [8] Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
    Eggermont, Alexander M. M.
    Chiarion-Sileni, Vanna
    Grob, Jean-Jacques
    Dummer, Reinhard
    Wolchok, Jedd D.
    Schmidt, Henrik
    Hamid, Omid
    Robert, Caroline
    Ascierto, Paolo A.
    Richards, Jon M.
    Lebbe, Celeste
    Ferraresi, Virginia
    Smylie, Michael
    Weber, Jeffrey S.
    Maio, Michele
    Konto, Cyril
    Hoos, Axel
    de Pril, Veerle
    Gurunath, Ravichandra Karra
    de Schaetzen, Gaetan
    Suciu, Stefan
    Testori, Alessandro
    [J]. LANCET ONCOLOGY, 2015, 16 (05) : 522 - 530
  • [9] The Hill equation and the origin of quantitative pharmacology
    Gesztelyi, Rudolf
    Zsuga, Judit
    Kemeny-Beke, Adam
    Varga, Balazs
    Juhasz, Bela
    Tosaki, Arpad
    [J]. ARCHIVE FOR HISTORY OF EXACT SCIENCES, 2012, 66 (04) : 427 - 438
  • [10] Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
    Joensuu, H
    Kellokumpu-Lehtinen, P
    Bono, P
    Alanko, T
    Kataja, V
    Asola, R
    Utriainen, T
    Kokko, R
    Hemminki, A
    Tarkkanen, M
    Turpeenniemi-Hujanen, T
    Jyrkkiö, S
    Flander, M
    Helle, L
    Ingalsuo, S
    Johansson, K
    Jääskeläinen, A
    Pajunen, M
    Rauhala, M
    Kaleva-Kerola, J
    Salminen, T
    Leinonen, M
    Elomaa, I
    Isola, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (08) : 809 - 820